N-terminus and C-terminus

The N-terminus is the amino end of a peptide chain; the opposite C-terminus is the carboxyl end, and sequences are written from N to C. Those ends matter because enzymes can start cutting there, while chemical caps such as N-terminal acetylation or C-terminal amidation can change a peptide’s charge, behavior, and resistance to breakdown.

What are the N-terminus and C-terminus?

The N-terminus carries the chain’s first amino acid and its available amino group; the C-terminus carries the last amino acid and its available carboxyl group. “Terminus” just means end. Every linear peptide therefore has a direction, rather like a sentence with a beginning and an ending.

The middle amino acids are joined through peptide bonds, so their backbone amino and carboxyl groups are already tied up. The groups left at the two outside edges give the chain its amino terminus and carboxyl terminus. A cyclic peptide joins its ends together, so that familiar two-ended picture no longer applies in the same way.

“N-terminal vs C-terminal” usually describes location, not two kinds of peptide. An N-terminal residue, cap, or fragment sits at the amino end. A C-terminal residue, cap, or fragment sits at the carboxyl end.

Why are peptide sequences written from N to C?

Peptide sequences are conventionally read from the N-terminus on the left to the C-terminus on the right. That direction makes the first letter the N-terminal amino acid and the final letter the C-terminal amino acid. Reverse the letters and you have described a different sequence, not the same chain viewed from the other side.

For example, EEMQRR begins with N-terminal glutamic acid (E) and ends with C-terminal arginine (R). The one-letter alphabet is compact, but it assumes the reader knows which way the chain runs. Our guide to how peptides are made explains how those amino acids become a chain.

Prefixes and suffixes can show that the ends are modified. In Ac-EEMQRR-NH2, Ac- is attached before the first residue at the N-terminal end, while -NH2 appears after the final residue at the C-terminal end. Neither cap adds another amino acid to the six-letter sequence.

Why do the two ends matter?

Peptide ends are exposed chemical handles, so changing one can alter charge, shape, enzyme recognition, or biological activity. Some protein-cutting enzymes work inward from an end: aminopeptidases attack the amino end, while carboxypeptidases attack the carboxyl end. A cap can remove the free group an enzyme expects to find.

That does not make “capped” a synonym for “long-lasting.” In a laboratory study using designed antimicrobial peptides in human serum, N-terminal acetylation increased resistance to proteases, but C-terminal amidation made little difference to proteolytic breakdown. Amidation did increase antimicrobial activity in that peptide set. The evidence tier here is in vitro—a serum experiment, not a trial showing that every capped peptide lasts longer in people.

The practical reading rule is modest: end modifications can matter, and their effect depends on the sequence and the job the peptide must do. A label alone cannot supply a human half-life.

What do N-terminal acetylation and C-terminal amidation mean?

N-terminal acetylation adds an acetyl group to the amino end, commonly written Ac-; C-terminal amidation converts the carboxyl end to an amide, commonly written -NH2. Both are forms of end capping. Chemists use them in natural-peptide research and synthetic peptide design, but the result is specific to the molecule.

The caps also change how the terminal charges behave. Acetylation neutralizes the amino end’s usual positive charge, while amidation neutralizes the carboxyl end’s usual negative charge. That can alter how a peptide interacts with water, membranes, enzymes, and its target. “Modified” therefore describes a structural fact; it does not, by itself, prove better absorption, effectiveness, or safety.

How does Argireline use both ends?

Argireline is a concrete two-cap example: its sequence is Ac-EEMQRR-NH2, meaning the N-terminus is acetylated and the C-terminus is amidated. PubChem records the molecule as acetyl hexapeptide-3, also known as acetyl hexapeptide-8. “Hexapeptide” counts the six amino acids between the caps.

Argireline is also described as being modeled on the N-terminal region of SNAP-25. Those are separate ideas: “N-terminal region” says where the copied fragment came from in the larger protein, while “N-terminally acetylated” says what was attached to Argireline’s own amino end.

The capped structure fits a familiar peptide-engineering strategy, but it does not prove that Argireline survives for a particular time in skin or in the body. That would require compound-specific stability or pharmacokinetic data. The sequence tells you what the molecule is; it does not quietly smuggle in a clinical result.

Is SNAP-8 capped the same way?

SNAP-8 uses the same two kinds of end cap: Ac-EEMQRRAD-NH2 shows an acetylated N-terminus and an amidated C-terminus. SNAP-8 has eight amino acids because AD extends the six-residue Argireline sequence before the terminal amide. The left-to-right rule makes that difference visible at a glance.

This is why one glossary page covers both ends. N-terminal and C-terminal language always describes a relationship within the same chain, and splitting the pair would leave two definitions repeatedly pointing back at each other. Read from Ac- or the first residue on the left, move toward the final residue or -NH2 on the right, and the notation stops looking like laboratory punctuation.